Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).

摘要: Some evidences suggest that obesity impairs the effectiveness of TNF inhibitors. We examined impact body mass index (BMI) on clinical abatacept in rheumatoid arthritis (RA) patients. This is a pooled analysis 10 prospective cohorts RA All patients with available BMI were included this study. The primary endpoint was drug retention different categories. Multivariable Cox regression used to estimate hazard ratios (HRs) for discontinuation. A secondary EULAR/LUNDEX response rates at 6/12 months. Of 2015 initiating therapy IV abatacept, 380 (18.9%) classified as obese. Obese had more functional disability, and less often RF positive. median time 1.91 years obese compared 2.12 years non-obese (p = 0.15). risk discontinuation not significantly overweight (HR 1.03 (95% CI 0.89-1.19)), or 1.08 0.89-1.30)) normal-weight Rheumatoid factor positivity reduced 0.83 0.72-0.95)), while previous biologic positively associated interruption (HRs increasing from 1.68 2.16 line treatments). attained similar Drug do seem be decreased by